Intensity Therapeutics Analyst Ratings
BenzingaMar 21 10:03 ET
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
BenzingaMar 21 10:06 ET
Intensity Therapeutics Analyst Ratings
BenzingaNov 14, 2023 09:24 ET
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
BenzingaAug 24, 2023 08:52 ET
Intensity Therapeutics Analyst Ratings
BenzingaAug 24, 2023 08:51 ET
Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12
BenzingaJul 18, 2023 06:56 ET
Intensity Therapeutics Analyst Ratings
BenzingaJul 18, 2023 06:56 ET
No Data
No Data